Compare ENR & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | MPLT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2015 | 2025 |
| Metric | ENR | MPLT |
|---|---|---|
| Price | $21.63 | $7.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $22.17 | ★ $26.54 |
| AVG Volume (30 Days) | ★ 851.7K | 422.3K |
| Earning Date | 11-17-2026 | 12-03-2026 |
| Dividend Yield | ★ 5.46% | N/A |
| EPS Growth | ★ 538.46 | 82.39 |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $0.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $15.75 | $7.46 |
| 52 Week High | $25.35 | $40.43 |
| Indicator | ENR | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 23.77 |
| Support Level | $19.68 | N/A |
| Resistance Level | $22.76 | $20.46 |
| Average True Range (ATR) | 0.80 | 0.60 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 62.79 | 8.81 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.